BridgeBio Pharma Inc (BBIO)
23.42
+0.18
(+0.77%)
USD |
NASDAQ |
Nov 22, 16:00
23.44
+0.02
(+0.09%)
After-Hours: 20:00
BridgeBio Pharma Revenue (TTM): 217.76M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 217.76M |
| June 30, 2024 | 219.12M |
| March 31, 2024 | 218.60M |
| December 31, 2023 | 9.303M |
| September 30, 2023 | 9.428M |
| June 30, 2023 | 5.675M |
| March 31, 2023 | 77.78M |
| Date | Value |
|---|---|
| December 31, 2022 | 77.65M |
| September 30, 2022 | 88.66M |
| June 30, 2022 | 90.67M |
| March 31, 2022 | 70.95M |
| December 31, 2021 | 69.72M |
| September 30, 2021 | 56.95M |
| June 30, 2021 | 62.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
5.675M
Minimum
Jun 2023
219.12M
Maximum
Jun 2024
91.07M
Average
74.30M
Median
Revenue (TTM) Benchmarks
| Pfizer Inc | 59.37B |
| Alnylam Pharmaceuticals Inc | 2.095B |
| Vertex Pharmaceuticals Inc | 10.63B |
| PTC Therapeutics Inc | 900.66M |
| Bristol-Myers Squibb Co | 47.44B |